Table 2.
Association between increased glucosinolate contents and increased expression of glucosinolate pathway genes in resistant and moderately resistant disease interactions.
| BN4098 × 00–100 s (moderately resistant interaction) | BN4303 × 03–02 s (moderately resistant interaction) | BN4303 × 00–100 s (resistant interaction) | |
|---|---|---|---|
| Aliphatic | — | GIV | GIV and GER |
| (ST5b–Bol026201, Bol026202) | (ST5b–Bol026201, Bol026202) | ||
| GSL-OH | |||
| (Bol033373) | |||
| Indolic | GBS | — | GBS |
| (ST5a-Bol026200) | (MYB34-Bol007760, ST5a-Bol026200) | ||
| MGBS | NGBS | ||
| (CYP81F4-Bol032712, CYP81F2-Bol026044) | (CYP81F4-Bol032712, Bol032714; CYP81F2-Bol026044) |
GIV, Glucoiberverin, GER, glucoerucin, GBS, glucobrassicin, NGBS, neoglucobrassicin and MGBS, methoxy-glucobrassicin.